MGMT and malignant glioma: As continuous low-dose TMZ has been shown to induce low yet detectable levels of mutations (phase II trial with recurrent malignant glioma patients [238]), a metronomic schedule involving low-dose TMZ is likely to represent an optimal option for accumulating immunogenic mutations notably in tumors in which MGMT is epigenetically silenced.